<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104113">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01786161</url>
  </required_header>
  <id_info>
    <org_study_id>P 002617</org_study_id>
    <nct_id>NCT01786161</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients</brief_title>
  <acronym>CIV</acronym>
  <official_title>Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vancomycin is an essential antimicrobial which is frequently used in the ICU for suspected
      methicillin-resistant Staphylococcus aureus (MRSA) infection. Therefore, it is vital to
      optimize the dosing of vancomycin for this critically ill population. The most efficacious
      method of administering vancomycin is debated in the literature. Since vancomycin is
      associated with slow bactericidal activity, it is important to closely monitor serum
      concentrations so as to achieve early target serum concentration, particularly when treating
      aggressive S. aureus infections. One study has shown that vancomycin  infused continuously
      may enable faster and more consistent achievement of a therapeutic serum concentration when
      compared to intermittent infusion. A faster achievement in the goal serum vancomycin
      concentration would be a protective factor for intensive care unit mortality in patients
      with MRSA infection.

      Currently in the surgical ICU (SICU) of our institute, vancomycin is administered based on a
      vancomycin dosing nomogram. Less than fifty percent of the ICU patients following this
      nomogram achieved target vancomycin concentration of 15 after 24 hours. To better achieve
      target vancomycin concentration in 24 hours, we developed a new vancomycin dosing nomogram
      with a continuous infusion. The aim is to determine which of the two dosing nomogram is more
      efficient and safer for SICU patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Frequency of achieving target vancomycin concentration</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of nephrotoxicity</measure>
    <time_frame>7 to 10 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To establish the relationship of vancomycin clearance with renal clearance</measure>
    <time_frame>7 to 10 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>MRSA - Methicillin Resistant Staphylococcus Aureus Infection</condition>
  <arm_group>
    <arm_group_label>Vancomycin with continuous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>continuous 24 hours intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin with intermittent dose interval</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>infusion rate 1000mg/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin continuous infusion</intervention_name>
    <description>Vancomycin 24 hour intravenous continuous infusion</description>
    <arm_group_label>Vancomycin with continuous infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin intermittent dosing interval</intervention_name>
    <description>Vancomycin intravenous infusion at rate 1000mg/hr</description>
    <arm_group_label>Vancomycin with intermittent dose interval</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and non-pregnant female &gt; 18 years of age admitted to Surgical ICUs with
             suspected infection

          -  Calculated creatinine clearance &gt; 60ml/min

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Allergic to vancomycin

          -  Calculated creatinine clearance &lt; 60ml/min

          -  Pregnant

          -  Vancomycin administration more than 8 hour and less than 24 hour prior to study
             enrollment

          -  Anticipated vancomycin treatment less than 2 days for surgical prophylaxis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsin Lin, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hsin Lin, PharmD</last_name>
    <email>hlin13@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin</last_name>
      <email>hlin13@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>February 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Hsin Jung Lin</investigator_full_name>
    <investigator_title>PharmD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
